With the mega investment, Merck will expand its high-potent active pharmaceutical ingredient (Hpapi) and antibody-drug conjugates (ADC) manufacturing capabilities. The new 6,500-sq m facility is expected to be one of the largest Hpapi manufacturing facilities capable of handling single-digit nanogram occupational exposure limit materials.
Read on